Wordt geladen...
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
INTRODUCTION: Drotrecogin alfa (activated; recombinant activated protein C) was shown to reduce 28-day all-cause mortality in patients with severe sepsis and to have an acceptable safety profile in 1690 patients studied in the F1K-MC-EVAD (PROWESS) trial. We analyzed all available data on the safety...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2003
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC270661/ https://ncbi.nlm.nih.gov/pubmed/12720562 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|